Gilead to brief US Congress on its pricing strategy for new oral Hep-C drug

US Congress demands briefing from Gilead on its pricing strategy for Sofosbuvir (Sovaldi)- new oral drug for Hep-C treatment for which it recently received marketing approval in US.

The Committee of Energy and Commerce, House of Congress asked for providing reasons for pricing the drug at cost of 84,000$ which will be un-affordable for majority of patients in the country. The letter sent to Gilead raised concern on the high cost despite of role played by the Federal Government in speeding up the approval for this drug and the savings arising from this process.

The Committee in specific asked Gilead to share its methodology used to establish price of Sovaldi and the discounts planned for low income patients, key government and private sector purchasers.

Read the full article here

This entry was posted in Hepatitis C, Pricing and tagged , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s